Natures Sunshine Products Inc

  • Health Care
  • Biotechnology: Pharmaceutical Preparations
  • www.natr.com
  • Earnings Score
  • Moat Score
  • Market Cap $252.13M
  • PE 15
  • Debt -
  • Cash $78.70M
  • EV -
  • FCF $12.69M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings$16.98M
EBIT$24.14M
ROE10%
ROA10%
FCF$12.69M
Equity$162.62M
Growth Stability-2%
PE14.85
PEG-5.46
PB1.55
P/FCF19.87
P/S0.57
Price/Cash0.31
Net Margins2%
Gross Margins71%
Op. Margins5%
Earnings CAGR12%
Sales Growth YoY3%
Sales Growth QoQ4%
Sales CAGR8%
FCF CAGR16%
Equity CAGR2%
Earnings Stability0.06
Earnings Growth YoY53%
Earnings Growth QoQ222%
Earnings CAGR 5Y-3%
Sales CAGR 5Y5%
FCF CAGR 5Y3%
Equity CAGR 5Y3%
Earnings CAGR 3Y0%
Sales CAGR 3Y0%
FCF CAGR 3Y15%
Equity CAGR 3Y3%
Market Cap$252.13M
Revenue$445.10M
Assets$245.33M
Cash$78.70M
Shares Outstanding18.5M
Earnings Score7%
Moat Score81%
Working Capital96.38M
Current Ratio2.44
Gross Profit$317.95M
Shares Growth 3y-2%
Equity Growth QoQ4%
Equity Growth YoY7%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Natures Sunshine Products Inc is a natural health and wellness company, primarily engaged in the manufacturing and selling of nutritional and personal care products. The company markets its products in Australia, Austria, Belarus, Canada, Colombia, Costa Rica, the Czech Republic, Denmark, the Dominican Republic, Ecuador, El Salvador, Finland, Germany, Guatemala, Honduras, Hong Kong, and in various other countries. The company operates in four segments namely, Asia, Europe, North America, and Others. It offers products related to general health, immunity, cardiovascular, digestive, personal care and weight management.

SEC Filings

Direct access to Natures Sunshine Products Inc (NATR) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Natures Sunshine Products Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Natures Sunshine Products Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 12%
Stability 6%
loading chart...

Natures Sunshine Products Inc Discounted Cash Flow

Fully customizable DCF calculator online for Natures Sunshine Products Inc.

= $377M
012345678910TV
fcf$13M$15M$17M$20M$23M$26M$30M$35M$40M$47M$54M$540M
DCF$13M$14M$15M$15M$16M$17M$18M$19M$20M$21M$208M
Value$377M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years09/201512/201712/201812/201912/202012/202112/202212/2023TTM
Net Margins--4%-0%2%6%6%-0%3%2%
ROA-2%3%8%9%13%7%8%10%
ROE--12%-1%5%14%18%-0%9%10%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years09/201512/201712/201812/201912/202012/202112/202212/2023TTM
Debt over FCF-2.62-00.150.13-0.340-
Debt over Equity-0.11-00.030.020.020-
Growth Stability-----100%-2%91%-2%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years09/201512/201712/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth--7%-1%6%15%-5%6%5%
Earnings YoY growth---91%-663%215%35%-101%-4K%-3%
Equity YoY growth--1%7%21%3%-9%8%3%
FCF YoY growth--238%-85%1K%-15%-125%-544%3%